Reuters logo
BRIEF-Shire's angioedema drug succeeds in late-stage study
2017年5月18日 / 上午11点18分 / 5 个月前

BRIEF-Shire's angioedema drug succeeds in late-stage study

May 18 (Reuters) - Shire Plc

* Shire’s investigational treatment lanadelumab reduces hereditary angioedema monthly attack rate by 87% versus placebo in phase 3 26-week pivotal trial

* Says data to serve as basis for U.S. BLA filing expected in Q4 2017 to Q1 2018

* Shire - study met its primary endpoint and all secondary endpoints with highly statistically significant, clinically meaningful results for all three lanadelumab treatment arms

* Shire Plc - lanadelumab was generally well tolerated over 26-week treatment period

* Says no treatment-related serious adverse events or deaths were reported

* Shire Plc - plans to submit a biologics license application (BLA) for evaluation by U.S. Food and Drug Administration (FDA) by late 2017 or early 2018 Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below